Aspire-Lakewood Holdings Inc(ASBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 7 at 4:00 PM ET (Korea 10/8 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -106.59 | Insider Own | 20.1% | Shs Outstand | 1.3M | Perf Week | 3.35% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.1M | Perf Month | -2.49% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 3.35% | Short Float | 3.1% | Perf Quarter | 42.17% |
| Income | -0.01B | P/S | 121.08 | EPS this Y | - | Inst Trans | 15.09% | Short Ratio | 0.91 | Perf Half Y | -75.83% |
| Sales | 0.00B | P/B | 0.95 | EPS next 5Y | - | ROA | -152.09% | Short Interest | 0.03M | Perf YTD | -94.55% |
| Book/sh | 9.08 | P/C | 0.99 | EPS past 3/5Y | - | ROE | -1032.14% | 52W High | -98.47% ($562.92) | Perf Year | -98% |
| Cash/sh | 8.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -93.97% | 52W Low | 160.8% ($3.31) | Perf 3Y | -99.93% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.71% | Gross Margin | 18.35% | Volatility(W/M) | 4.73% 7.08% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -0.62 | Sales Y/Y TTM | - | Oper. Margin | -7259.85% | ATR (14) | 0.57 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.81 | EPS Q/Q | 97.46% | Profit Margin | -11314.12% | RSI (14) | 52.19 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.99 | Sales Q/Q | - | SMA20 | 0.38% ($8.6) | Beta | 0.18 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 5.88% ($8.15) | Rel Volume | 0.33 | Prev Close | $8.76 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -68.4% ($27.31) | Avg Volume(3M) | 0.04M | Price | $8.63 |
| IPO | 2022/4/11 | Option/Short | No/Yes | Trades | 556 | Volume | 12,494 | Change | -1.48% |
An early-stage biopharmaceutical company focused on developing novel drug delivery technologies, utilizing sublingual delivery (under the tongue) to develop a range of products including heart medications, pain relievers, and hormone therapies. The company is pursuing early monetization through its Buzz Bomb caffeine product.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual That is 33% of its average volume.
ASBP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $12,108. Peers typically go for $38.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #54 of 57 in the industry
Based on market cap of $12M.
GTEC#53 Greenland Technologies Holding Corp $21M PER 1.3 ASBP#54 Aspire-Lakewood Holdings Inc $12M PER - 
INEO#55 INNEOVA Holdings Ltd $9M PER - 
WKSP#56 Worksport Ltd $6M PER - 
FRSX#57 Foresight Autonomous Holdings Ltd ADR $5M PER - 
FAQ
What kind of company is ASBP?
ASBP belongs to the Consumer Cyclical sector and operates in the Auto Parts industry.
What is the market cap of ASBP?
The market cap of ASBP is approximately $12M, ranking 5,428 within its sector.
What is the 52-week high and low for ASBP?
ASBP has recorded a 52-week high of $562.92 and a low of $3.31.
